FIELD: medicine.
SUBSTANCE: group of inventions refers to treating diabetic nephropathy. Disclosed is a method for preventing or treating diabetic nephropathy by administering to a subject a pharmaceutical composition containing fimasartan, a pharmaceutically acceptable salt thereof or a hydrate or solvate thereof. What is also disclosed is using fimasartan, its pharmaceutically acceptable salt or its hydrate or solvate for preventing or treating diabetic nephropathy.
EFFECT: group of inventions widens the range of drugs for treating diabetic nephropathy.
6 cl, 2 dwg, 3 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITIONS CONTAINING CARBAMOYLOXYARYLALCANOYLARYLPIPERAZINE COMPOUND | 2011 |
|
RU2630619C2 |
| NEW GLUTAMINE CYCLASE INHIBITOR AND ITS APPLICATION | 2018 |
|
RU2791703C2 |
| NEW INHIBITOR OF GLUTAMINYL CYCLASE AND ITS USE | 2017 |
|
RU2665633C1 |
| USE OF CARBAMATE COMPOUND FOR PREVENTION, RELIEF, OR TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY OR PERIPHERAL NEUROPATHY INDUCED BY CHEMOTHERAPY | 2019 |
|
RU2783733C1 |
| COMPOSITION FOR PREVENTING OR TREATING RENAL DISEASES, CONTAINING DPP-IV INHIBITOR | 2014 |
|
RU2652343C2 |
| AGENT FOR PROPHYLAXIS AND TREATMENT OF DIABETIC COMPLICATIONS | 1996 |
|
RU2173148C2 |
| USE OF RKS INHIBITORS IN DIABETES RELATED COMPLICATIONS | 2007 |
|
RU2447892C2 |
| THERAPEUTIC DRUG OR PREVENTIVE THERAPEUTIC AGENT FOR DIABETIC NEPHROPATHY | 2017 |
|
RU2735538C1 |
| PHARMACEUTICAL COMBINED DRUG | 2014 |
|
RU2639818C2 |
| TABLET AND METHOD OF ITS PREPARATION | 2019 |
|
RU2796301C2 |
